Ayşegül BAYIR, Hasan KARA, Aysel KIYICI, Bahadır ÖZTÜRK, Abdullah SİVRİKAYA, Fikret AKYÜREK

Pregnancy-associated plasma protein A and procalcitonin as markers of myocardial injury in patients with acute coronary syndrome

To evaluate pregnancy-associated plasma protein A (PAPP-A), ischemia-modified albumin (IMA), procalcitonin, and troponin I levels as diagnostic markers of acute coronary syndrome in patients admitted to the emergency department. Materials and methods: The serum PAPP-A, IMA, procalcitonin, and troponin I levels were measured in 100 patients with acute coronary syndrome admitted to the emergency department and 100 healthy control subjects. Results: Patients with acute coronary syndrome had significantly greater mean serum PAPP-A (patients, 10 ± 10 mIU/L; control subjects, 6 ± 10 mIU/L; P =< 0.001), procalcitonin (patients, 2 ± 10 µg/L; control subjects, 0.4 ± 2 µg/L; P =< 0.001), and troponin I levels (patients, 6 ± 8 µg/L; control subjects, 0.2 ± 0.3 µg/L; P =< 0.001) than control subjects. There was no difference in mean IMA levels between patients and control subjects. There were no significant correlations between PAPP-A levels and IMA, procalcitonin, or troponin I levels in patients with acute coronary syndrome. Conclusion: The PAPP-A, procalcitonin, and troponin I levels were increased in patients with acute coronary syndrome. Therefore, elevated PAPP-A and procalcitonin levels, in addition to troponin I levels, may be useful markers of myocardial injury on admission to the emergency department.

Anahtar Kelimeler:

Diagnosis, emergency department, heart, infarction, PAPP-A, troponin I

Pregnancy-associated plasma protein A and procalcitonin as markers of myocardial injury in patients with acute coronary syndrome

Keywords:

Diagnosis, emergency department, heart, infarction, PAPP-A, troponin I,

PDF

___

Qin QP, Laitinen P, Majamaa-Voltti K, Eriksson S, Kumpula EK, Pettersson K. Release pattern of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J 2002; 36: 358–361.
Qin QP, Wittfooth S, Pettersson K. Measurement and clinical significance of circulating PAPP-A in ACS patients. Clin Chim Acta 2007; 380: 59–67.
Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022– 1029.
Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006; 108: 410–411.
Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, Januzzi JL, Jesse RL, Kaski JC, Kontos MC et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. Am Heart J 2006; 152: 253–262.
Picariello C, Lazzeri C, Valente S, Chiostri M, Gensini GF. Procalcitonin in acute cardiac patients. Intern Emerg Med 2011; 6: 245–252. 9. Kafkas N, Venetsanou K, Patsilinakos S, Voudris V, Antonatos D, Kelesidis K, Baltopoulos K, Maniatis P, Cokkinos DV. Procalcitonin in acute myocardial infarction. Acute Card Care 2008; 10: 30–36.
Geppert A, Steiner A, Delle-Karth G, Heinz G, Huber K. Usefulness of procalcitonin for diagnosing complicating sepsis in patients with acute cardiogenic shock. Intensive Care Med 2003; 29: 1384–1389.
Bar-Or D, Curtis G, Rao N, Bampos N, Lau E. Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur J Biochem 2001; 268: 42–47.
Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007; 45: 261–262.
Iversen KK, Dalsgaard M, Teisner AS, Schoos M, Teisner B, Nielsen H, Clemmensen P, Grande P. Usefulness of pregnancy- associated plasma protein A in patients with acute coronary syndrome. Am J Cardiol 2009; 104: 1465–1471.
Bonaca MP, Scirica BM, Sabatine MS, Jarolim P, Murphy SA, Chamberlin JS, Rhodes DW, Southwick PC, Braunwald E, Morrow DA. Prospective evaluation of pregnancy-associated plasma protein-A and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 2012; 60: 332–338.
Lund J, Qin QP, Ilva T, Nikus K, Eskola M, Porela P, Kokkala S, Pulkki K, Pettersson K, Voipio-Pulkki LM. Pregnancy- associated plasma protein A: a biomarker in acute ST-elevation myocardial infarction (STEMI). Ann Med 2006; 38: 221–228.
Keating L, Benger JR, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. The PRIMA study: presentation ischaemia- modified albumin in the emergency department. Emerg Med J 2006; 23: 764–768.
Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, Goodacre S. Utility of admission cardiac troponin and “Ischemia Modified Albumin” measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006; 23: 256–261.
Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29–34.
Lin RMH, Fatovich DM, Grasko JM, Vasikaran SD. Ischaemia modified albumin cannot be used for rapid exclusion of acute coronary syndrome. Emerg Med J 2010; 27: 668–671.
Hjortshİj S, Kristensen SR, Ravkilde J. Diagnostic value of ischemia-modified albumin in patients with suspected acute coronary syndrome. Am J Emerg Med 2010; 28: 170–176.
Shen XL, Lin CJ, Han LL, Lin L, Pan L, Pu XD. Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome. Int J Cardiol 2011; 149: 296–298.
Pantazopoulos I, Papadimitriou L, Dontas I, Demestiha T, Iakovidou N, Xanthos T. Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 2009; 80: 306–310.
Wudkowska A, Goch J, Goch A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol Pol 2010; 68: 431–437.
Remskar M, Horvat M, Hojker S, Noc M. Procalcitonin in patients with acute myocardial infarction. Wien Klin Wochenschr 2002; 114: 205–210.
Picariello C, Lazzeri C, Attanà P, Chiostri M, Gensini GF, Valente S. The impact of admission procalcitonin on prognosis in acute coronary syndromes: a pilot study. Biomarkers 2012; 17: 56–61.